Adalvo is excited to announce our expansion within the US market through a new strategic distribution and collaboration agreement with Sandoz, a global leader in off-patent (generic and biosimilar) medicines, for six high value products, indicated in various treatments within the Oncology and Antibiotic segments.
These products, which are slated for near-to mid-term launches beginning in 2024, have a total addressable market size of approximately $3.0 billion (as per IQVIA MAT Feb 2023 Sales data), and our flexible business approach will strengthen our presence within the dynamic and changing US environment.
This strategic collaboration is a clear demonstration of our capabilities, as we set our sights on surpassing our current EU/RoW boundaries and firmly establishing ourselves as a major player in the global market.
Adalvo’s US strategy is as unique as its foundation. We have approached the US market strategically, offering differentiated and high value products. We continue to collaborate with strategic partners such as Sandoz, to contribute to the wellbeing of patients worldwide. Adalvo has accessed over 100 markets to date, and with our expansion within the US we are able to address over 95% of the global pharmaceutical market worldwide.